Clinical Trial Update: Study of Efficacy and Safety of Secukinumab in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial update on secukinumab for moderate-to-severe chronic plaque-type psoriasis; results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Plaque Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-12-30